Proteomic analysis of striatum from MPTP-treated marmosets (Callithrix jacchus) with l-DOPA-Induced dyskinesia of differing severity

Journal of Molecular Neuroscience

Volumn 52, Issue 2, 2014, Pages 302-312

  Hurley, Michael J ^a,b   Jackson, Michael J ^a   Smith, Lance A ^a   Rose, Sarah ^a   Jenner, Peter ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Dyskinesia; l DOPA; MPTP; Parkinson's disease; Proteome; Striatum

Indexed keywords

ANIMALS; CALLITHRIX; DYSKINESIAS; LEVODOPA; MPTP POISONING; NEOSTRIATUM; PROTEOME;

EID: 84894247704     PISSN: 08958696     EISSN: 15591166     Source Type: Journal    
DOI: 10.1007/s12031-013-0145-y     Document Type: Article

References (26)

1. Blandini F, Armentero MT (2012) New pharmacological avenues for the treatment of l-DOPA-induced dyskinesias in Parkinson's disease: targeting glutamate and adenosine receptors. Expert Opin Investig Drugs 21:153-168
2. Centonze D, Picconi B, Gubellini P, Bernardi G, Calabresi P (2001) Dopaminergic control of synaptic plasticity in the dorsal striatum. Eur J Neurosci 13:1071-1077
3. Ghosh A, Roy A, Liu X et al (2007) Selective inhibition of NF-kappaB activation prevents dopaminergic neuronal loss in a mouse model of Parkinson's disease. Proc Natl Acad Sci U S A 104:18754-18759
4. Hashimoto T, Hussien R, Cho HS, Kaufer D, Brooks GA (2008) Evidence for the mitochondrial lactate oxidation complex in rat neurons: demonstration of an essential component of brain lactate shuttles. PLoS One 3:e2915
5. Huot P, Johnston TH, Koprich JB, Fox SH, Brotchie JM (2013) The pharmacology of l-DOPA-induced dyskinesia in Parkinson's disease. Pharmacol Rev 65:171-222
6. Iravani MM, McCreary AC, Jenner P (2012) Striatal plasticity in Parkinson's disease and l-DOPA induced dyskinesia. Parkinsonism Relat Disord 18(Suppl 1):S123-S125
7. Jackson MJ, Smith LA, Al-Barghouthy G, Rose S, Jenner P (2007) Decreased expression of l-DOPA-induced dyskinesia by switching to ropinirole in MPTP-treated common marmosets. Exp Neurol 204:162-170
8. Kultima K, Scholz B, Alm H et al (2006) Normalization and expression changes in predefined sets of proteins using 2D gel electrophoresis: a proteomic study of l-DOPA induced dyskinesia in an animal model of Parkinson's disease using DIGE. BMC Bioinforma 7:475
9. Lees AJ, Hardy J, Revesz T (2009) Parkinson's disease. Lancet 373:2055-2066
10. Liu F, Rehmani I, Esaki S et al (2013) Pirin is an iron-dependent redox regulator of NF-kappaB. Proc Natl Acad Sci U S A 110:9722-7
11. Marchler-Bauer A, Lu S, Anderson JB et al (2011) CDD: a conserved domain database for the functional annotation of proteins. Nucleic Acids Res 39:D225-D229
12. Mondal S, Roy A, Jana A, Ghosh S, Kordower JH, Pahan K (2012) Testing NF-kappaB-based therapy in hemiparkinsonian monkeys. J Neuroimmune Pharmacol 7:544-556
13. Pappin DJ, Hojrup P, Bleasby AJ (1993) Rapid identification of proteins by peptide-mass fingerprinting. Curr Biol 3:327-332
14. Pearce RK, Jackson M, Smith L, Jenner P, Marsden CD (1995) Chronic l-DOPA administration induces dyskinesias in the 1-methyl-4- phenyl-1,2,3,6- tetrahydropyridine-treated common marmoset (Callithrix Jacchus). Mov Disord 10:731-74
15. Quistorff B, Secher NH, Van Lieshout JJ (2008) Lactate fuels the human brain during exercise. FASEB J 22:3443-3449
16. Scholz B, Svensson M, Alm H et al (2008) Striatal proteomic analysis suggests that first l-DOPA dose equates to chronic exposure. PLoS One 3:e1589
17. 2+ channel reduces development of abnormal involuntary movement in the rat model of l-3,4-dihydroxyphenylalanine-induced dyskinesia. Biol Psychiatry 65:518-526
18. Smith LA, Jackson MJ, Al-Barghouthy G et al (2005) Multiple small doses of levodopa plus entacapone produce continuous dopaminergic stimulation and reduce dyskinesia induction in MPTP-treated drug-naïve primates. Mov Dis 20(3):306-314
19. 3 agonist piribedil reduces the expression of dyskinesia while maintaining effective motor activity in MPTP-treated primates. Clin Neuropharmacol 29:112-125
20. Soderstrom KE, O'Malley JA, Levine ND, Sortwell CE, Collier TJ, Steece-Collier K (2010) Impact of dendritic spine preservation in medium spiny neurons on dopamine graft efficacy and the expression of dyskinesias in parkinsonian rats. Eur J Neurosci 31:478-490
21. Stephan H, Baron G, Schwerdtfeger W (1980) The brain of the common marmoset: Callithrix jacchus. Springer, New York
22. Surmeier DJ, Guzman JN, Sanchez-Padilla J, Goldberg JA (2011) The origins of oxidant stress in Parkinson's disease and therapeutic strategies. Antioxid Redox Signal 14:1289-1301
23. Valastro B, Dekundy A, Krogh M et al (2007) Proteomic analysis of striatal proteins in the rat model of l-DOPA-induced dyskinesia. J Neurochem 102:1395-1409
24. van Hall G, Stromstad M, Rasmussen P et al (2009) Blood lactate is an important energy source for the human brain. J Cereb Blood Flow Metab 29:1121-1129
25. Wolf E, Seppi K, Katzenschlager R et al (2010) Long-term antidyskinetic efficacy of amantadine in Parkinson's disease. Mov Disord 25:1357-1363
26. Yanez M, Gil-Longo J, Campos-Toimil M (2012) Calcium binding proteins. Adv Exp Med Biol 740:461-482